SCYNEXIS

Research Capabilities ADMET & Bioanalytical Services

Essential Capabilities in Support of Drug Discovery and Development

The bioavailability of any molecule depends on its absorption, metabolism and distribution in humans. To support both lead optimization and candidate selection, SCYNEXIS provides rapid generation of reliable ADMET and pharmacokinetic (PK) data on compounds in discovery through NDA filing. SCYNEXIS rapidly screens for properties such as metabolic stability and cytotoxicity to prioritize and differentiate lead series based on those key ADMET parameters.

Lead optimization projects can also be guided by plasma stability studies, permeability assays and metabolite identification. In support of preclinical and clinical development, SCYNEXIS performs analyses of compounds in various matrices according to current GLP guidelines. In addition, SCYNEXIS can customize protocols and reports based on therapeutic areas and customer’s specifications.

In Vitro ADMET Capabilities

Cytochrome P₄₅₀ Isozyme Assays

Human Recombinant
Microsome-Based Assays

Metabolic Stability

Rodent, Dog and Human
Hepatocytes and Microsomes

Cytotoxicity and Cell-Based Assays

Variety of Tissue Cell Lines
Variety of Endpoints
Client-Specific Assays

Bioanalytical Capabilities

Sample Preparation

Tissue Extraction
Microtiter and Online SPE
Liquid Handlers

Triple-Quadrupole MS

Tandem-MS (MRM and SRM) Quantitation

LC-NMR

PD Studies

N-in-1 PK Screening

Metabolite ID

GLP-Compliant Studies